Bone Marrow News and Research RSS Feed - Bone Marrow News and Research

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.
SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

The Fred Hutchinson Cancer Research Center Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recently recognized for outperforming its anticipated one-year survival rate for allogeneic transplant patients. [More]
Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy. [More]
CUMC researchers identify that OCR stem cells can regenerate bone and cartilage in mice

CUMC researchers identify that OCR stem cells can regenerate bone and cartilage in mice

A stem cell capable of regenerating both bone and cartilage has been identified in bone marrow of mice. The discovery by researchers at Columbia University Medical Center is reported today in the online issue of the journal Cell. [More]
New device holds promise for improving the delivery of stem cell therapy for non-healing fractures

New device holds promise for improving the delivery of stem cell therapy for non-healing fractures

A new device that can rapidly concentrate and extract young cells from irrigation fluid used during orthopaedic surgery holds promise for improving the delivery of stem cell therapy in cases of non-healing fractures. UC Davis surgeons plan to launch a "proof-of-concept" clinical trial to test the safety and efficacy of the device in the coming months. [More]
Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Features of the blast phase, such as blast cell morphology and accompanying cytogenetic changes, vary between chronic myeloid leukaemia patients who received tyrosine kinase inhibitor therapy and those treated in the pre-TKI era, research shows. [More]
CML mouse model reveals previously unreported facets of disease

CML mouse model reveals previously unreported facets of disease

A humanised murine model of chronic phase chronic myeloid leukaemia, developed by a Swedish research team, provides insight into previously unexplored characteristics of the disease. [More]
Research findings may lead to new therapeutic target for AML treatment

Research findings may lead to new therapeutic target for AML treatment

A study by the Cancer Science Institute of Singapore at the National University of Singapore has found new interactions between two molecules involved in acute myeloid leukaemia (AML), STAT3 and PRL-3, which may offer a new therapeutic target for cancer treatment. [More]
Johns Hopkins-led study offers strategy to eradicate HIV

Johns Hopkins-led study offers strategy to eradicate HIV

Luring dormant HIV out of hiding and destroying its last cure-defying holdouts has become the holy grail of HIV eradication, but several recent attempts to do so have failed. Now the findings of a Johns Hopkins-led study reveal why that is and offer a strategy that could form a blueprint for a therapeutic vaccine to eradicate lingering virus from the body. [More]
Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences. [More]
Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS). [More]
BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem. [More]
Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

The risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer remains very small, but it is twice as high as previously reported, according to results of a new study led by researchers at the Johns Hopkins Kimmel Cancer Center. [More]
Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system. [More]
C3BS enrols 240th patient in CHART-1 European trial of C-Cure for treatment of congestive heart failure

C3BS enrols 240th patient in CHART-1 European trial of C-Cure for treatment of congestive heart failure

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the enrolment of the 240th patient in its CHART-1 European trial for C-Cure, the first and only stem cell therapeutic using guided stem cells for the treatment of congestive heart failure. [More]
Novel marker may help doctors choose most effective treatment for older patients with AML

Novel marker may help doctors choose most effective treatment for older patients with AML

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML). [More]
Apheresis: A potent therapeutic in extracorporeal photopherisis

Apheresis: A potent therapeutic in extracorporeal photopherisis

Apheresis, the simple process of drawing blood, becomes a powerful therapeutic in extracorporeal photopherisis (ECP) according to clinicians and scientists who met at the NIH State of the Science Symposium in Therapeutic Apheresis. Nora Ratcliffe, MD, of Dartmouth Hitchcock, looked at current methodology and opportunities for research in a paper recently published in Transfusion Medicine Review, titled "National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis." [More]
Young patients at risk for intellectual decline after bone marrow transplantation

Young patients at risk for intellectual decline after bone marrow transplantation

Toddlers who undergo total body irradiation in preparation for bone marrow transplantation are at higher risk for a decline in IQ and may be candidates for stepped up interventions to preserve intellectual functioning, St. Jude Children's Research Hospital investigators reported. [More]
Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation. [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
PRM-151 compound shows positive results for treating advanced myelofibrosis

PRM-151 compound shows positive results for treating advanced myelofibrosis

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer. [More]